Researchers from the Connecticut Gastroenterology Institute and other research centers suggest there may be a new "promising" treatment for patients who suffer from irritable bowel syndrome, according to a news release.
The study, which was published in the New England Journal of Medicine, evaluated rifaximin, a minimally absorbed antibiotic, to see its effectiveness in treating IBD. Results from the study showed that patients who were assigned to take rifaximin reported significantly more relief of global IBS symptoms during the first four weeks after treatment than the control group. More patients in the rifaximin group than the control group also reported relief from bloating.
Read the study about rifaximin and IBD.
Read other coverage about GI treatments:
- Decreasing Patient Discomfort and Pain During GI Procedures: Q&A With Dr. Ralph McKibbin of Allegheny Regional Endoscopy
- Study: More Colonoscopy Screening Options Confuse Patients
- Research Suggests High Endoscopy Completion Rates Tied to Fewer Missed Colorectal Cancers
The study, which was published in the New England Journal of Medicine, evaluated rifaximin, a minimally absorbed antibiotic, to see its effectiveness in treating IBD. Results from the study showed that patients who were assigned to take rifaximin reported significantly more relief of global IBS symptoms during the first four weeks after treatment than the control group. More patients in the rifaximin group than the control group also reported relief from bloating.
Read the study about rifaximin and IBD.
Read other coverage about GI treatments:
- Decreasing Patient Discomfort and Pain During GI Procedures: Q&A With Dr. Ralph McKibbin of Allegheny Regional Endoscopy
- Study: More Colonoscopy Screening Options Confuse Patients
- Research Suggests High Endoscopy Completion Rates Tied to Fewer Missed Colorectal Cancers